Monthly Archives: August 2021
LTE Reply to 21-00786 and 21-01414
Posted in News
Comments Off on LTE Reply to 21-00786 and 21-01414
The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
S AND AIMS: Increased permeability is implicated in the pathogenesis of intestinal disease. In vitro and in vivo studies have linked downregulation of the scaffolding protein ZO-1, encoded by the TJP1 gene, to increased tight junction permeability. Thi… Continue reading
Posted in News
Comments Off on The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
Risankizumab (RZB) is a monoclonal antibody against interleukin-23, a key cytokine in the pathogenesis of inflammatory bowel disease. Phase 2 studies have shown efficacy and safety of RZB in patients with Crohn’s disease (CD). Here we report results of… Continue reading
Posted in News
Comments Off on 775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
713b A Multi-Systems Approach with Big Data from Adverse Event Reporting and Health Records, Clinical Biospecimens, and Experimental Animal Data Reveal That Retinoids Impact Asparaginase-Associated Pancreatitis Outcomes in Leukemic Patients
Asparaginase is a crucial cornerstone chemotherapy for the most common cancer in children, acute lymphoblastic leukemia (ALL). However, a major concern is that 5-10% of all asparaginase users develop the painful, life-threatening complication of pancre… Continue reading
Posted in News
Comments Off on 713b A Multi-Systems Approach with Big Data from Adverse Event Reporting and Health Records, Clinical Biospecimens, and Experimental Animal Data Reveal That Retinoids Impact Asparaginase-Associated Pancreatitis Outcomes in Leukemic Patients
775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
IL-6 trans-signaling blockade inhibits chronic inflammation in human lamina propria1. Trans-signaling inhibition may have safety advantages over pan-IL-6 inhibitors (i.e. IL-6 or IL-6R antibodies) by preserving membrane IL-6R signaling. We evaluated th… Continue reading
Posted in News
Comments Off on 775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
The development of type II diabetes mellitus (T2DM) is strongly associated with consuming a western diet, high in sugars and fats. Metabolites from both dietary fats and carbohydrates can regulate each other through transcriptional regulators like carb… Continue reading
Posted in News
Comments Off on 713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
Head-to-head trials are important to inform patient (pt) and physician choice. We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve pts with moderate-to-severe Crohn’s disease (CD). Continue reading
Posted in News
Comments Off on 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
713d Downregulation of Apolipoprotein H Induce Hepatocyte Steatosis to Promote Gut Microbiota Dysbiosis in Chronic Hepatitis B Infection
Apolipoprotein H (apoH) is produced by hepatocytes and also an acute phase protein in hepatitis B virus (HBV) infection. We found HBV and the large surface antigen upregulate apoH expression, which inhibits HBsAg secretion and then induces ER stress. A… Continue reading
Posted in News
Comments Off on 713d Downregulation of Apolipoprotein H Induce Hepatocyte Steatosis to Promote Gut Microbiota Dysbiosis in Chronic Hepatitis B Infection
Covering the Cover
The optimal age to stop endoscopic surveillance for nondysplastic Barrett’s esophagus depends on sex and comorbidity level. Continue reading
Posted in News
Comments Off on Covering the Cover